ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)

Study Summary

This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.

Conditions

Acute Hepatic Porphyria

Interventions / Drugs

View on ClinicalTrials.gov ↗

Sponsor

ALNY

Alnylam Pharmaceuticals

RNAi Therapeutics

F28/100

Study Details

Enrollment150 participants

Primary Completion—

Lead SponsorAlnylam Pharmaceuticals

Data Retrieved2026-04-11 02:53:26.219224+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.